Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Daiichi Sankyo's COVID-19 vaccine selected by Japanese drug discovery body

Daiichi Sankyo Co said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development.

The vaccine, known as DS-5670, was picked for the second round of AMED's program dedicated to COVID-19 research. Daiichi Sankyo is aiming to begin clinical studies of the vaccine around March 2021 in collaboration with the University of Tokyo.

(Reporting by Rocky Swift; Editing by Toby Chopra)

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.